Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Massimo Di Maio

Showing results (271-280 of 418) with videos related to

Pageof 42
Sort By:
The Lancet. Oncology|May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) studyCesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 24, 2009
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005Prisco Piscitelli, Antonio Santoriello, Franco M Buonaguro, et al.
Critical Reviews in Oncology/Hematology|December 18, 2025
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysisFabio Salomone, Massimo Di Maio, Angela Viggiano, et al.
Clinical Medicine (London, England)|May 28, 2026
A FeAsibility items Checklist for assessing implementation characTeristics of patient reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): development and evaluationAsad Bhatty, Chris Wilkinson, Visvesh Jeyalan, et al.
Tumori|January 7, 2023
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM societyAndrea Milani, Valentina Tuninetti, Sandro Pignata, et al.
European Journal of Cancer (Oxford, England : 1990)|January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trialsMassimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
BMJ Oncology|January 31, 2025
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyLaura Marandino, Federica Trastu, Eleonora Ghisoni, et al.
Pediatric Nephrology (Berlin, Germany)|July 27, 2020
Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatmentsAurélia Bertholet-Thomas, Catherine Guittet, Maria A Manso-Silván, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 22, 2012
The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge recordsPrisco Piscitelli, Maddalena Barba, Massimo Crespi, et al.
International Journal of Cancer|April 16, 2022
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumabGiulia Martini, Davide Ciardiello, Marcello Dallio, et al.
Pageof 42

Showing results (271-280 of 418) with videos related to

Sort By:
Pageof 42
The Lancet. Oncology|May 22, 2007
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) studyCesare Gridelli, Ciro Gallo, Anna Ceribelli, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 24, 2009
Incidence of breast cancer in Italy: mastectomies and quadrantectomies performed between 2000 and 2005Prisco Piscitelli, Antonio Santoriello, Franco M Buonaguro, et al.
Critical Reviews in Oncology/Hematology|December 18, 2025
Correlation of ORR and PFS with OS outcomes in phase III trials of immunotherapy in advanced NSCLC: Systematic review and meta-analysisFabio Salomone, Massimo Di Maio, Angela Viggiano, et al.
Clinical Medicine (London, England)|May 28, 2026
A FeAsibility items Checklist for assessing implementation characTeristics of patient reported Outcome measures in Research, Regulation and Routine clinical care (FACTOR3): development and evaluationAsad Bhatty, Chris Wilkinson, Visvesh Jeyalan, et al.
Tumori|January 7, 2023
Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM societyAndrea Milani, Valentina Tuninetti, Sandro Pignata, et al.
European Journal of Cancer (Oxford, England : 1990)|January 5, 2010
Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trialsMassimo Di Maio, Nicola Lama, Alessandro Morabito, et al.
BMJ Oncology|January 31, 2025
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research studyLaura Marandino, Federica Trastu, Eleonora Ghisoni, et al.
Pediatric Nephrology (Berlin, Germany)|July 27, 2020
Efficacy and safety of an innovative prolonged-release combination drug in patients with distal renal tubular acidosis: an open-label comparative trial versus standard of care treatmentsAurélia Bertholet-Thomas, Catherine Guittet, Maria A Manso-Silván, et al.
Journal of Experimental & Clinical Cancer Research : CR|November 22, 2012
The burden of breast cancer in Italy: mastectomies and quadrantectomies performed between 2001 and 2008 based on nationwide hospital discharge recordsPrisco Piscitelli, Maddalena Barba, Massimo Crespi, et al.
International Journal of Cancer|April 16, 2022
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumabGiulia Martini, Davide Ciardiello, Marcello Dallio, et al.
Pageof 42